Trials / Completed
CompletedNCT00262483
Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C
A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects With Hepatitis C
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (planned)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To assess the safety of the combination of VX-950, Pegasys and Copegus in subjects with hepatitis C.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VX-950 | |
| DRUG | ribavirin | |
| DRUG | peginterferon alfa-2a |
Timeline
- Start date
- 2005-12-01
- Completion
- 2006-04-01
- First posted
- 2005-12-06
- Last updated
- 2007-12-21
Locations
2 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT00262483. Inclusion in this directory is not an endorsement.